molecules of the month


p97/VCP ATPase inhibitor (PDE6 off-target)

Ph. I in cancer (discont., dyschromatopsia)

from HTS of NIH compound library

J. Pharmacol. Exp. Ther., Apr. 30, 2021

Cleave Therapeutics, San Francisco, CA

1 min read

The Cleave Therapeutics p97 (VCP) inhibitor, CB-5083, was a Ph. I clinical candidate for cancer that was terminated due to vision side effects including causing patients to see unusual colors (dyschromatopsia). In this paper, the authors suggest that the visual impairment was due to the compounds inhibition of the phosphodiesterase-6 (PDE6), which is involved in photoreceptor signal transduction. Fortunately, the effect on vision appears to be reversible, and the authors suggest CB-5083 should be re-evaluated in the clinic. This work suggests that PDE6 should be a more routinely screened against off-target, and preclinical ERG recordings can be used to assess functional safety relevance for compounds with in vitro PDE6 signals.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: